Johnson & Johnson
Johnson & Johnson (JNJ) Financial Performance & Income Statement Overview
Explore the financials of Johnson & Johnson (JNJ), including yearly and quarterly data on income, cash flow, and balance sheets.
Johnson & Johnson (JNJ) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Johnson & Johnson JNJ financial performance.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $21.89B | $22.52B | $22.47B |
| Cost of Revenue | $0.00 | $7.36B | $7.13B | $6.96B |
| Gross Profit | $16.11B | $14.54B | $15.39B | $15.51B |
| Gross Profit Ratio | $0.00 | $0.66 | $0.68 | $0.69 |
| R&D Expenses | $3.52B | $3.23B | $5.30B | $4.95B |
| SG&A Expenses | $5.89B | $5.01B | $6.25B | $5.28B |
| Operating Expenses | $9.40B | $8.24B | $11.55B | $10.23B |
| Total Costs & Expenses | $0.00 | $15.59B | $18.68B | $17.19B |
| Interest Income | $0.00 | $332.00M | $281.00M | $292.00M |
| Interest Expense | $48.00M | $204.00M | $137.00M | $193.00M |
| Depreciation & Amortization | $0.00 | $1.77B | $1.90B | $1.85B |
| EBITDA | $6.71B | $15.61B | $5.92B | $5.38B |
| EBITDA Ratio | $0.00 | $0.71 | $0.26 | $0.24 |
| Operating Income | $6.71B | $6.30B | $3.84B | $5.28B |
| Operating Income Ratio | $0.00 | $0.29 | $0.17 | $0.23 |
| Other Income/Expenses (Net) | -$219.00M | $7.33B | $46.00M | -$1.94B |
| Income Before Tax | $6.49B | $13.63B | $3.89B | $3.34B |
| Income Before Tax Ratio | $0.00 | $0.62 | $0.17 | $0.15 |
| Income Tax Expense | $954.00M | $2.63B | $456.00M | $644.00M |
| Net Income | $5.54B | $11.00B | $3.43B | $2.69B |
| Net Income Ratio | $0.00 | $0.50 | $0.15 | $0.12 |
| EPS | $2.77 | $4.57 | $1.43 | $1.12 |
| Diluted EPS | $2.77 | $4.54 | $1.41 | $1.11 |
| Weighted Avg Shares Outstanding | $2.42B | $2.41B | $2.41B | $2.41B |
| Weighted Avg Shares Outstanding (Diluted) | $2.42B | $2.42B | $2.43B | $2.43B |
Over the last four quarters, Johnson & Johnson's revenue moved from $22.47B in Q3 2024 to $0.00 in Q2 2025. Operating income in Q2 2025 was $6.71B, with a strong operating margin of N/A. Despite fluctuations in R&D and SG&A expenses, EBITDA for Johnson & Johnson remained robust at $6.71B, reflecting operational efficiency. Net income dropped to $5.54B, with an EPS of $2.77. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan